Abstract
LNCaP prostatic cancer cells are characterized by having a PTEN mutation, low levels of type 1 insulin-like growth factor receptor (IGF-IR) and no IRS-1, one of the major substrates of the IGF-IR. The absence of IRS-1, an activator of PI3-kinase, is compensated in these cells by the mutation in PTEN, an inhibitor of PI3-kinase. However, IGF-IR signaling in the absence of IRS-1 can cause cell differentiation and growth arrest. We hypothesized that these three characteristics may not be unrelated, specifically that, together, they may favor the metastatic spread of prostatic cancer cells without decreasing their growth potential. In support of this hypothesis, we report here that: (1) IRS-1 expression increases cell adhesion and decreases cell motility; (2) over-expression of the IGF-IR, in the absence of IRS-1, causes growth arrest and (3) a combination of IGF-IR and IRS-1 restores the transformed phenotype of LNCaP cells. These findings suggest a mechanism by which prostatic cancer cells can achieve metastatic potential without interfering with their growth potential.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Angelloz-Nicoud P and Binoux M . 1995 Endocrinology 136: 5485–5492
Baserga R, Prisco M and Hongo A . 1999 Contemporary Endocrinology The IGF System Rosenfeld R and Roberts Jr C edHumana Press, Inc Totawa, NJ pp 329–353
Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linchan WM and Topalian SI . 1997 Cancer Res 57: 995–1002
Brooks PC, Klemke RL, Schoen S, Lewis JM, Schwartz MA and Cheresh DA . 1997 J Clin Invest 99: 1390–1398
Burfeind P, Chernicky CL, Rininsland F, Ilan J and Ilan I . 1996 Proc Natl Acad Sci USA 93: 7263–7268
Carson JP, Kulik G and Weber MJ . 1999 Cancer Res 59: 49–53
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennenkens CH and Pollak M . 1998 Science 279: 563–566
Cohen P, Peehl DM, Lamson G and Rosenfeld RG . 1991 J Clin Endocrinol Metabol 73: 401–407
D'Ambrosio C, Keller SR, Morrione A, Lienhard GE, Baserga R and Surmacz E . 1995 Cell Growth Differ 6: 557–562
Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK and Steck PA . 1999 Cancer Res 59: 2551–2556
Dunn SE, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R and Barrett JC . 1998 Cancer Res 58: 3353–3361
Feshchenko EA, Shore SK and Tsygankov AY . 1999 Oncogene 18: 3703–3715
Furnari FB, Hong L, Huang HJS and Cavenee WK . 1997 Proc Natl Acad Sci USA 94: 12479–12484
Furnari FB, Huang HJS and Cavenee WK . 1998 Cancer Res 58: 5002–5008
Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC and Chung LWK . 1992 Cancer Res 52: 1598–1605
Guilherme A and Czech MP . 1998 J Biol Chem 273: 33119–33122
Guilherme A, Torres K and Czech MP . 1998 J Biol Chem 273: 22899–22903
Guvakova MA and Surmacz E . 1997 Exp Cell Res 231: 149–162
Huynh H, Seyam RM and Brock GB . 1998 Cancer Res 58: 215–218
Jones JI, Prevette T, Cockerman A and Clemmons DR . 1996 Proc Natl Acad Sci USA 93: 2482–2487
Li DM and Sun H . 1998 Proc Natl Acad Sci USA 95: 15406–15411
Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N and Parsons R . 1998 Cancer Res 58: 5667–5672
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Ouc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann C, Tycko B, Hibshoosh H, Wigler MH and Parsons R . 1997 Science 275: 1943–1947
Mantzoros CS, Tzonou A, Signorelo LB, Stampler M, Trichopoulos D and Adami HO . 1997 Brit J Cancer 76: 1115–1118
Myers Jr MG, Grammar TC, Wang LM, Sun XJ, Pierce JH, Blenis J and White MF . 1994 J Biol Chem 269: 28783–28789
Myers Jr MG, Mendez R, Shi P, Pierce JH, Rhoads R and White MF . 1998 J Biol Chem 273: 26908–26914
Ogawa W, Matozaki T and Kasuga M . 1998 Mol Cell Biochem 182: 13–22
Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B and Baserga R . 1999 Mol Cell Biol 19: 7203–7215
Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D and Baserga R . 1993 Cancer Res 53: 1102–1106
Plymate SR, Bae VL, Maddison L, Quinn LS and Ware JL . 1997 Endocrinology 138: 1728–1735
Reiss K, D'Ambrosio C, Tu X, Tu C and Baserga R . 1998 Clinical Cancer Res 4: 2647–2655
Reiss K, Yumet G, Shan S, Huang Z, Alnemri E, Srinivasula SM, Wang JY, Morrione A and Baserga R . 1999 J Cell Physiol 181: 124–135
Romano G, Prisco M, Zanocco-Marani T, Peruzzi F, Valentinis B and Baserga R . 1999 J Cell Biochem 72: 294–310
Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A and Baserga R . 1993 Proc Natl Acad Sci USA 90: 11217–11221
Soos G, Jones RF, Haas GP and Wang CY . 1997 Anticancer Res 17: 4253–4258
Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF and Tavtigian SV . 1997 Nature Genetics 15: 356–362
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R and Yamada K . 1998 Science 280: 1614–1617
Tamura M, Gu J, Danen EHJ, Takino T, Miyamoto S and Yamada KM . 1999 J Biol Chem 274: 20693–20703
Tanaka S, Ito T and Wands JR . 1996 J Biol Chem 271: 14610–14616
Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC and Chung LWK . 1994 Cancer Res 54: 2577–2581
Valentinis B, Reiss K and Baserga R . 1998 J Cell Physiol 176: 648–657
Valentinis B, Morrione A, Peruzzi F, Prisco M, Reiss K and Baserga R . 1999a Oncogene 18: 1827–1836
Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, Soddu S, Cristofanelli B, Sacchi A and Baserga R . 1999b J Biol Chem 274: 12423–12430
Vuori K and Ruoslahti E . 1994 Science 266: 1576–1578
White MF . 1998 Recent Prog Horm Res 53: 119–138
Wick W, Furnari FB, Naumann U, Cavenee WK and Weller M . 1999 Oncogene 18: 3936–3943
Wu X, Senechal K, Neshat MS, Whang YE and Sawyers CL . 1998 Proc Natl Acad Sci USA 95: 15587–15591
Zheng B and Clemmons DR . 1998 Proc Natl Acad Sci USA 95: 11217–11222
Acknowledgements
This work is supported by Grants CA 53484 and CA 78890 from the National Institutes of Health.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reiss, K., Wang, JY., Romano, G. et al. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 19, 2687–2694 (2000). https://doi.org/10.1038/sj.onc.1203587
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203587
Keywords
This article is cited by
-
Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy
Archives of Pharmacal Research (2017)
-
IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination
Oncogene (2014)
-
miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells
Journal of Cancer Research and Clinical Oncology (2014)
-
Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy
Cancer and Metastasis Reviews (2014)
-
Is PTEN loss associated with clinical outcome measures in human prostate cancer?
British Journal of Cancer (2008)